Intestinal epithelial cell surface glycoproteins

Intestinal epithelial cell surface glycoproteins represent a broad class of membrane-bound proteins characterized by extensive glycosylation, located on the apical and basolateral surfaces of enterocytes and other specialized intestinal cells. This group encompasses several functionally distinct families, including cell adhesion molecules like Glycoprotein A33 (GPA33), Epithelial Cell Adhesion Molecule (EpCAM), and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5), as well as various mucins, nutrient transporters, and receptors like Guanylate cyclase C. These proteins are essential for maintaining the structural integrity of the intestinal barrier, mediating cell-cell communication, and facilitating the selective absorption of nutrients and ions. In clinical oncology, specific members of this class, such as GPA33 and CEACAM5, are frequently overexpressed in colorectal and gastric cancers, serving as critical targets for monoclonal antibodies, radioimmunotherapy, and antibody-drug conjugates. While these targets offer high tumor specificity in the context of colorectal cancer, their presence in normal intestinal tissue can lead to dose-limiting gastrointestinal toxicities, such as severe diarrhea or mucosal inflammation, necessitating careful therapeutic window management.

Other names

Intestinal cell surface glycoproteinsEnterocyte surface glycoproteinsIntestinal membrane glycoproteinsGlycoprotein A33 (GPA33)Epithelial cell adhesion molecule (EpCAM)Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)Intestinal epithelial cell surface glycoprotein (gp180)Guanylate cyclase C (GC-C)

Drugs targeting these glycoproteins employ various mechanisms depending on the specific molecule. Monoclonal antibodies (e.g., huA33, labetuzumab) typically induce antibody-dependent cellular cytotoxicity (ADCC) or deliver cytotoxic payloads like radioisotopes to malignant cells. Agonists of specific glycoproteins, such as linaclotide targeting guanylate cyclase C, activate intracellular signaling pathways (e.g., cGMP production) to regulate fluid secretion and motility. Other agents may block cell-cell adhesion or modulate immune interactions at the intestinal mucosal surface.